A recombinant human broadly neutralizing monoclonal antibody that binds the HIV-1 Env gp120 CD4-binding site to block virus–CD4 interaction and entry; neutralizes diverse HIV-1 strains and can mediate Fc-dependent effector functions (ADCC/ADCP). The LS Fc mutations enhance FcRn binding and extend serum half-life.
Recombinant human broadly neutralizing monoclonal antibody that binds the HIV-1 Env gp120 CD4-binding site, blocking gp120–CD4 interaction and viral entry; neutralizes diverse HIV-1 strains and can engage Fc-dependent effector functions (ADCC/ADCP) against infected cells. LS Fc mutations enhance FcRn binding to extend serum half-life.
YES
DIRECT
Binds gp120 on infected cells and engages FcγR-expressing effector cells to mediate ADCC/ADCP (and possibly CDC), leading to killing of target-expressing cells.
Off-the-shelf dual-binding antibodies (commonly CD3×CD20) that redirect T cells to kill CD20-positive B cells.
Off‑the‑shelf bispecific antibody that simultaneously binds CD3 on T cells and CD20 on B cells, forming an immunologic synapse to activate and redirect cytotoxic T cells for MHC‑independent lysis of CD20‑positive malignant B cells via perforin/granzyme release and cytokine‑mediated killing.
NO
INDIRECT
The bispecific binds CD3 on T cells to recruit and activate them against CD20+ B cells; activated T cells kill CD20-expressing cells via perforin/granzyme and cytokines, while CD3+ T cells are not the killed population.
Monoclonal antibody linked to a cytotoxic payload to deliver chemotherapy directly to antigen-positive B cells.
A monoclonal antibody targets an antigen on malignant B cells, is internalized, and releases a linked cytotoxic payload inside the cell, causing targeted chemotherapy-induced cell death (e.g., microtubule or DNA damage) in antigen-positive B cells; may also retain Fc-mediated effector functions.
YES
DIRECT
Antibody binds CD19 on B cells, is internalized, and releases a cytotoxic payload (e.g., microtubule or DNA-damaging agent) that kills the antigen-positive cell; Fc functions may add ADCC/CDC.
Monoclonal antibody linked to a cytotoxic payload to deliver chemotherapy directly to antigen-positive B cells.
A monoclonal antibody targets an antigen on malignant B cells, is internalized, and releases a linked cytotoxic payload inside the cell, causing targeted chemotherapy-induced cell death (e.g., microtubule or DNA damage) in antigen-positive B cells; may also retain Fc-mediated effector functions.
YES
DIRECT
An anti-CD20 antibody-drug conjugate binds CD20 on B cells, is internalized, and releases a cytotoxic payload (e.g., microtubule or DNA-damaging agent) that kills antigen-positive cells; Fc effector functions may also contribute (ADCC/CDC).
Anti-CD20 monoclonal antibody that mediates complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis of B cells.
Chimeric anti‑CD20 monoclonal antibody that binds CD20 on pre‑B and mature B cells and depletes them via complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity/phagocytosis, and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and kills them via complement-dependent cytotoxicity (MAC lysis), Fc-mediated ADCC/ADCP by immune effector cells, and induction of apoptosis.